Bank Julius Baer & Co
VKTX icon

Bank Julius Baer & Co’s Viking Therapeutics VKTX Stock Holding History

Bank Julius Baer & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Hold
12,000
– – ﹤0.01% 451
2026
Q1 		$390K Hold
12,000
– – ﹤0.01% 452
2025
Q4 		$422K Hold
12,000
– – ﹤0.01% 440
2025
Q3 		$315K Sell
12,000
-5,008
-29% -$149K ﹤0.01% 456
2025
Q2 		$451K Buy
17,008
+9,008
+113% +$237K ﹤0.01% 394
2025
Q1 		$193K Buy
8,000
+3,020
+61% +$95.4K ﹤0.01% 427
2024
Q4 		$221K Buy
4,980
+345
+7% +$19.7K ﹤0.01% 416
2024
Q3 		$348K Buy
+4,635
New +$272K ﹤0.01% 363
2021
Q2 		– Sell
-6,400
Closed -$40K – 877
2021
Q1 		$40K Sell
6,400
-1,593
-20% -$11.2K ﹤0.01% 689
2020
Q4 		$45K Buy
7,993
+2,993
+60% +$18.1K ﹤0.01% 696
2020
Q3 		$29K Hold
5,000
– – ﹤0.01% 643
2020
Q2 		$36K Sell
5,000
-1
-0% -$7 ﹤0.01% 587
2020
Q1 		$23K Buy
+5,001
New +$30.7K ﹤0.01% 578

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank Julius Baer & Co's VKTX Position: Q2 2026 in Review

Bank Julius Baer & Co held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 12,000 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #451.

Bank Julius Baer & Co first reported a position in VKTX in Q1 2020 and has held it in 13 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bank Julius Baer & Co held 12,000 shares of Viking Therapeutics worth $468K as of Q2 2026.
  • Bank Julius Baer & Co left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #451 holding.
  • Bank Julius Baer & Co first reported a position in Viking Therapeutics in Q1 2020 and has held it in 13 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.